Last reviewed 2026-05-20 · How we verify

Lopain

Grünenthal GmbH · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Lopain is a Small molecule drug developed by Grünenthal GmbH. It is currently in Phase 1 development. Also known as: MTX-071.

Lopain is a small molecule that acts as a vanilloid receptor agonist. It is being studied for the treatment of osteoarthritis of the knee, specifically for reducing chronic joint pain.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Lopain
Also known as	MTX-071
Sponsor	Grünenthal GmbH
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint Pain (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lopain CI brief — competitive landscape report
Lopain updates RSS · CI watch RSS
Grünenthal GmbH portfolio CI

Frequently asked questions about Lopain

What is Lopain?

Lopain is a Small molecule drug developed by Grünenthal GmbH.

Who makes Lopain?

Lopain is developed by Grünenthal GmbH (see full Grünenthal GmbH pipeline at /company/gr-nenthal-gmbh).

Is Lopain also known as anything else?

Lopain is also known as MTX-071.

What development phase is Lopain in?

Lopain is in Phase 1.

Manufacturer: Grünenthal GmbH — full pipeline
Therapeutic area: All drugs in Pain
Also known as: MTX-071

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing